Patents by Inventor Ryan N. Constantine

Ryan N. Constantine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazole derivates
    Patent number: 8735599
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 27, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Xia Yia, Rustum S. Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan N. Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Quinazolinone Compounds as Anticancer Agents
    Publication number: 20110190293
    Abstract: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Weibo Wang, Liana M. Lagniton, Ryan N. Constantine, Manoj C. Desai
  • Quinazolinone compounds as anticancer agents
    Patent number: 7939539
    Abstract: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: May 10, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Liana M. Lagniton, Ryan N. Constantine, Manoj C. Desai
  • SUBSTITUTED QUINOLINE DERIVATIVES
    Publication number: 20090028858
    Abstract: The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: September 30, 2008
    Publication date: January 29, 2009
    Inventors: Weibo Wang, Ryan N. Constantine, Liana Marie Lagniton, Kenneth Bair
  • Substituted quinoline derivatives
    Patent number: 7452996
    Abstract: The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: November 18, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Ryan N. Constantine, Liana Marie Lagniton, Kenneth Bair
  • Mitotic Kinesin Inhibitors
    Publication number: 20080249112
    Abstract: The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: formula (I).
    Type: Application
    Filed: April 6, 2005
    Publication date: October 9, 2008
    Applicant: CHIRON CORPORATION
    Inventors: Weibo Wang, Ryan N. Constantine, Liana M. Lagniton
  • Heteroaryl-fused pyrimidinyl compounds as anticancer agents
    Patent number: 7345046
    Abstract: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: March 18, 2008
    Assignee: Chiron Corporation
    Inventors: Weibo Wang, Liana Marie Lagniton, Ryan N. Constantine, Matthew T. Burger
  • Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
    Patent number: 7326711
    Abstract: Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: February 5, 2008
    Assignee: Chiron Corporation
    Inventors: Weibo Wang, Ryan N. Constantine, Liana Marie Lagniton, Sabina Pecchi, Matthew T. Burger, Manoj C. Desai